MEDEZE Wins Frost & Sullivan 2025 Award, Reinforcing Its Leadership in Stem Cell and Advanced Medical Innovation in Southeast Asia

26.12.2025

MEDEZE Wins Frost & Sullivan 2025 Award, Reinforcing Its Leadership in Stem Cell and Advanced Medical Innovation in Southeast Asia

Medeze Group Public Company Limited (“MEDEZE”) has received the 2025 “Southeast Asian Stem Cell Banking & Regenerative Medicine Company of the Year” award from Frost & Sullivan, reaffirming its leadership in innovation, international standards, and readiness for the future of precision medicine across Southeast Asia.

Dr. Veerapol Khemarangsan, Chief Executive Officer of Medeze Group Public Company Limited, or MEDEZE, announced that the Company has been honored with the “2025 Southeast Asian Stem Cell Banking & Regenerative Medicine Company of the Year” award by Frost & Sullivan, a globally recognized research and strategic consulting firm. The award represents the highest level of Best Practices Recognition, granted to organizations demonstrating excellence in innovation, operations, financial performance, and positive impact on consumers and the overall healthcare system.

This achievement further confirms MEDEZE’s sustained leadership over the past eight years, during which the Company has consistently been recognized for best practices within the Southeast Asian stem cell banking and regenerative medicine industry.

MEDEZE distinguishes itself from other industry players through its fully integrated business model, encompassing the entire value chain—from biological sample collection and laboratory analysis to cell isolation and expansion, high-standard cryogenic storage, and readiness for clinical application under the regulatory framework governing Advanced Therapy Medicinal Products (ATMPs).

In addition, MEDEZE is the only stem cell bank in Thailand certified with Cleanroom Class 100 by the National Environmental Balancing Bureau (NEBB) of the United States, and fully compliant with standards set by the Association for the Advancement of Blood & Biotherapies (AABB). The Company also maintains a network of more than 260 partner hospitals and has expanded its operations across multiple Southeast Asian countries, aligning with the rapid growth of precision medicine and regenerative healthcare throughout the region.

The Company’s achievements over the past eight years reflect its ability to uphold the highest industry standards amid increasing competition and rapid technological advancement. This success reinforces the confidence of patients, physicians, business partners, and investors in MEDEZE as a stable, resilient, and future-ready industry leader with strong long-term growth potential.

“MEDEZE does not view itself merely as a stem cell banking service provider,” said Dr. Weeraphol. “We see ourselves as part of the future medical infrastructure—integrating research, technology, clinical practice, and regulatory standards to support the development of advanced therapies (ATMPs) and personalized medicine in a tangible way. We believe this award will serve as a key driving force for MEDEZE to continue innovating and expanding sustainably on a global scale.”

MEDEZE Wins Frost & Sullivan 2025 Award, Reinforcing Its Leadership in Stem Cell and Advanced Medical Innovation in Southeast Asia

IR Press Releases